Patients with unilateral CP were younger (median 8, range 1-19 years) than those with bilateral CP(12.5, 4-19 years; p
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Objectives: National Swedish guidelines for treatment with botulinum toxin in children and adolescents with cerebral palsy(CP) include evaluation of self-estimated effects of treatment.
📊
Temel Bulgular & Veri:We hypothesized that the treatment effect subsides after thefirst injection.Methods: Children (or their parents), receiving their first botulinum toxin treatment of upper limb before the age of 20 years,filled in a questionnaire (visual analog scale; VAS) six weeks after each injection.Results: Eighty-one out of 95 children or adolescents were evaluated (35% girls; 65% boys; 61% unilateral; 34% bilateral; 5% dyskinetic).
💡
Sonuç & Katkı:Patients with unilateral CP were younger (median 8, range 1-19 years) than those with bilateral CP(12.5, 4-19 years; p
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Abstract
Objectives: National Swedish guidelines for treatment with botulinum toxin in children and adolescents with cerebral palsy(CP) include evaluation of self-estimated effects of treatment. We hypothesized that the treatment effect subsides after thefirst injection.Methods: Children (or their parents), receiving their first botulinum toxin treatment of upper limb before the age of 20 years,filled in a questionnaire (visual analog scale; VAS) six weeks after each injection.Results: Eighty-one out of 95 children or adolescents were evaluated (35% girls; 65% boys; 61% unilateral; 34% bilateral; 5% dyskinetic). Patients with unilateral CP were younger (median 8, range 1-19 years) than those with bilateral CP(12.5, 4-19 years; p
🔖
Bu Makaleye Atıf Yap
LINNE, L., SOMMERSTEIN, K., CHEMNITZ, A., ERIXON, H., DAHLIN, L. B. (2022). Self-estimated effect of treatment with botulinum toxin in the upper extremity of children with Cerebral Palsy (CP). Hand and Microsurgery, Cilt: 7 - Sayı: 3, 135–142. https://ajindex.com/articles/533950
Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, et al. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 2005;47:571-6
Himmelmann K, Hagberg G, Beckung E, Hagberg B, Uvebrant P. The changing panorama of cerebral palsy in Sweden. IX. Prevalence and origin in the birth-year period 1995-1998. Acta Paediatr 2005;94:287-94
Cerebral palsy. Available via: https://en.wikipedia. org/wiki/Cerebral_palsy (Accessed: August 30, 2018
Prevalence and characteristics of children with cerebral palsy in Europe. Dev Med Child Neurol 2002;44:633-40
Wasiak J, Hoare B, Wallen M. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev 2004:CD003469
Reeuwijk A, van Schie PE, Becher JG, Kwakkel G. Effects of botulinum toxin type A on upper limb function in children with cerebral palsy: a systematic review. Clin Rehabil 2006;20:375-87
Quality Standards Subcommittee of the American Academy of N, the Practice Committee of the Child Neurology S, Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010;74:336-43
Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000;137:331-7
Arner M, Himmelmann K, Ponten E, Stankovic N, Hansson T, Dahlin LB. [Upper extremity botulinum toxin treatment in cerebral palsy. Treatment guidelines the first step towards national cooperation][Article in Swedish]. Lakartidningen 2008;105:3009-13
Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-94
Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 2004;19 Suppl 8:S92-S100
Herrmann J, Geth K, Mall V, Bigalke H, Schulte Monting J, et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 2004;55:732-5
Lim EC, Seet RC. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion. Acta Neurol Scand 2008;117:73-